Boston Scientific Corp. reported a strong start to 2025, with first-quarter net sales reaching $4.663 billion, marking a 20.9% increase on a reported basis, 22.2% on an operational basis, and 18.2% on an organic basis compared to the previous year. The company's GAAP net income attributable to common stockholders was $674 million, or $0.45 per share, up from $0.33 per share last year, while adjusted earnings per share stood at $0.75, surpassing the company's guidance range and up from $0.56 last year. The company's performance was driven by significant growth across its segments. The MedSurg segment saw a reported growth of 11.7%, with operational and organic growth at 12.8% and 5.3% respectively. The Cardiovascular segment reported a 26.2% increase in sales on a reported basis, with operational and organic growth at 27.6% and 25.6% respectively. Regionally, the U.S. led with a 31.1% increase in sales, reaching $2.96 billion, followed by the Asia-Pacific region at 8.2% with sales of $701 million, and Europe, Middle East, and Africa at 5.5% with sales of $846 million. Latin America and Canada saw a 4.4% increase, with sales amounting to $155 million. Boston Scientific also provided guidance for the second quarter and full year of 2025. For the second quarter, the company anticipates net sales growth between 17.5% and 19.5% on a reported basis, and 13% to 15% on an organic basis, with GAAP EPS expected between $0.45 and $0.47, and adjusted EPS between $0.71 and $0.73. For the full year, net sales are projected to grow 15% to 17% on a reported basis and 12% to 14% on an organic basis, with GAAP EPS forecasted at $1.86 to $1.93 and adjusted EPS at $2.87 to $2.94.